Currently, the diagnosis of LS requires patients/kindreds to fulfill the Amsterdam or revised Bethesda criteria, with demonstration of absent MMR protein expression on tumor immunohistochemistry and/or microsatellite instability (MSI) genotyping supporting the diagnosis (2). Here, MRC1 is linked to neoplasm.